Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.2K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

540
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
540
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

303
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
303
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

424
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
424
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

735
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
735
Coronary Circulation01:21

Coronary Circulation

7.6K
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
7.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Randomized Clinical Trial Comparing Bare-Metal Stents Plus Colchicine Versus Drug-Eluting Stents for Preventing Adverse Cardiac Outcomes: Three-Year Follow-Up Results of the ORal Colchicine in Argentina (ORCA) Trial.

Journal of clinical medicine·2025
Same author

Colchicine for secondary prevention of vascular events: a meta-analysis of trials.

European heart journal·2025
Same author

Intravascular imaging-guided versus angiography-guided percutaneous coronary intervention in patients with diabetes mellitus: Rationale and design of an international, multicenter, randomized IVI-DIABETES trial.

American heart journal·2025
Same author

Do Drug-eluting Stents Increase Noncardiac Mortality?

The Canadian journal of cardiology·2025
Same author

Causes of Death After Coronary Revascularization in Patients With Diabetes.

The Annals of thoracic surgery·2024
Same author

Major Bleeding and Mortality After Revascularization of Left Main Disease.

Journal of the American College of Cardiology·2024

関連する実験動画

Updated: Feb 14, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.3K

冠動脈バイパス移植後の死亡率と冠動脈疾患のためのステントを挿入した皮膚経冠動脈介入の比較:個々の患者のデータをまとめた分析

Stuart J Head1, Milan Milojevic1, Joost Daemen2

  • 1Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands.

Lancet (London, England)
|February 27, 2018
PubMed
まとめ

冠動脈バイパス移植 (CABG) は,多血管冠動脈疾患における皮膚経冠動脈介入 (PCI) よりも,特に糖尿病患者の死亡率に優れていることが示されています. しかし,左側主疾患の結果は同様です.

さらに関連する動画

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

19.3K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

10.0K

関連する実験動画

Last Updated: Feb 14, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.3K
Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

19.3K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

10.0K

科学分野:

  • 心臓病科
  • 介入心臓科
  • 心臓外科

背景:

  • 多くの試験では,冠動脈バイパス移植 (CABG) と冠動脈疾患における皮膚経冠動脈介入 (PCI) を比較した.
  • 以前の研究では,これらの再血管化の戦略の間の死亡率の違いを検出する能力が不足していました.

研究 の 目的:

  • ランダム化臨床試験から得られた個々の患者のデータを体系的に検討し,分析する.
  • 多血管性または左主動動脈疾患の患者におけるCABGとPCIの5年間の全因死亡率を比較する.

主な方法:

  • 2017年7月19日までのランダム化試験の系統的レビュー,急性心筋梗塞のない多血管性または左主冠動脈疾患の患者を含む.
  • ステントを使ったPCIとCABGを比較した11件の臨床試験 (11,518人) の個々の患者のデータを集約した分析で,追跡期間の中央値は3. 8年であった.
  • すべての原因による死亡率を推定し比較するために,カプラン・マイヤー分析とコックスの比例リスクモデルを使用し,一貫性のためにサブグループ分析を行いました.

主要な成果:

  • 5年間の全原因死亡率はPCI後の11. 2%であり,CABG後の9. 2%であった (HR 1. 20,p=0. 0038).
  • CABGは,多血管疾患の患者 (11. 5% vs. 8. 9%,HR 1.28,p=0. 0019),特に糖尿病患者 (15. 5% vs. 10. 0%,HR 1.48,p=0. 004) の死亡率に有意な効果を示した.
  • 死亡率はPCIとCABGで左動脈大動脈疾患の死亡率に類似した (10. 7% vs 10. 5%,HR 1.07,p=0. 52).

結論:

  • 冠動脈バイパス移植は,多血管冠動脈疾患の患者,特に糖尿病と複雑な冠動脈解剖を持つ患者において,皮膚経冠動脈介入よりも死亡率が優れている.
  • 左側主動脈疾患の患者では,CABGとPCIの間で有意な死亡率の違いは見られなかった.
  • これらの再血管化戦略の死亡率の違いを完全に解明するには,さらなる長期追跡が必要である.